X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4614) 4614
Book Review (826) 826
Publication (362) 362
Conference Proceeding (10) 10
Magazine Article (5) 5
Dissertation (3) 3
Book / eBook (2) 2
Book Chapter (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4330) 4330
index medicus (4238) 4238
female (2639) 2639
male (2449) 2449
quinazolines - adverse effects (2294) 2294
quinazolines - therapeutic use (2282) 2282
middle aged (2222) 2222
oncology (2084) 2084
aged (2030) 2030
quinazolines - administration & dosage (1609) 1609
adult (1606) 1606
lung neoplasms - drug therapy (1412) 1412
carcinoma, non-small-cell lung - drug therapy (1205) 1205
erlotinib hydrochloride (1078) 1078
antineoplastic agents - therapeutic use (1070) 1070
gefitinib (1065) 1065
treatment outcome (1048) 1048
chemotherapy (958) 958
antineoplastic agents - adverse effects (936) 936
cancer (875) 875
receptor, epidermal growth factor - antagonists & inhibitors (869) 869
antineoplastic combined chemotherapy protocols - therapeutic use (865) 865
erlotinib (859) 859
aged, 80 and over (766) 766
quinazolines - pharmacology (764) 764
protein kinase inhibitors - therapeutic use (696) 696
pharmacology & pharmacy (649) 649
animals (610) 610
care and treatment (609) 609
lung neoplasms - pathology (593) 593
protein kinase inhibitors - adverse effects (586) 586
antineoplastic combined chemotherapy protocols - adverse effects (546) 546
disease-free survival (545) 545
tyrosine kinase inhibitor (514) 514
growth-factor receptor (512) 512
therapy (499) 499
epidermal growth factor (475) 475
lung cancer, non-small cell (468) 468
receptor, epidermal growth factor - genetics (466) 466
mutation (464) 464
cell lung-cancer (463) 463
carcinoma, non-small-cell lung - pathology (456) 456
quinazolines - pharmacokinetics (443) 443
trial (439) 439
medicine & public health (434) 434
dose-response relationship, drug (433) 433
hematology, oncology and palliative medicine (428) 428
research (426) 426
adenocarcinoma - drug therapy (419) 419
egfr (414) 414
neoplasm staging (411) 411
breast neoplasms - drug therapy (400) 400
lung neoplasms - genetics (384) 384
drug therapy (371) 371
lung cancer (371) 371
antineoplastic agents - administration & dosage (349) 349
clinical trials (342) 342
drug administration schedule (342) 342
respiratory system (341) 341
clinical trials as topic (336) 336
analysis (334) 334
lung neoplasms - mortality (320) 320
carcinoma, non-small-cell lung - genetics (318) 318
abridged index medicus (310) 310
survival (304) 304
non-small cell lung cancer (301) 301
carcinoma, non-small-cell lung - mortality (298) 298
neoplasms - drug therapy (296) 296
protein kinase inhibitors - administration & dosage (296) 296
survival analysis (290) 290
open-label (289) 289
antibodies, monoclonal, humanized (281) 281
breast cancer (280) 280
mice (276) 276
trastuzumab (274) 274
expression (268) 268
metastasis (268) 268
tyrosine (266) 266
deoxycytidine - analogs & derivatives (265) 265
prognosis (265) 265
antineoplastic agents - pharmacology (262) 262
retrospective studies (262) 262
antineoplastic agents (261) 261
receptor, epidermal growth factor - metabolism (261) 261
disease progression (259) 259
epidermal growth factor receptor (259) 259
lapatinib (259) 259
combination (249) 249
time factors (248) 248
tumors (248) 248
survival rate (247) 247
pharmacokinetics (246) 246
antimitotic agents (238) 238
administration, oral (235) 235
bevacizumab (235) 235
pharmacology/toxicology (233) 233
efficacy (230) 230
follow-up studies (230) 230
mutations (226) 226
1st-line treatment (225) 225
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4347) 4347
Japanese (65) 65
Chinese (50) 50
French (49) 49
German (43) 43
Spanish (29) 29
Russian (10) 10
Italian (8) 8
Czech (6) 6
Polish (6) 6
Danish (5) 5
Dutch (5) 5
Hungarian (4) 4
Norwegian (3) 3
Hebrew (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medical Oncology, ISSN 1357-0560, 10/2017, Volume 34, Issue 10, pp. 1 - 9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 384 - 393
Journal Article
Haematologica, ISSN 0390-6078, 05/2004, Volume 89, Issue 5, pp. 520 - 527
Dept. Int Medicine, University Hospital, Uppsala, Sweden. Gunnar.Birgegard@medsci.uu.se BACKGROUND AND OBJECTIVES: Although anagrelide is widely used in the... 
Thrombocythemia | Myeloproliferative disease | Anagrelide | thrombocythemia | MANAGEMENT | HEMATOLOGY | anagrelide | myeloproliferative disease | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Male | Patient Dropouts | Thrombocytosis - etiology | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Heart Rate - drug effects | Thrombocytosis - drug therapy | Quinazolines - therapeutic use | Quinazolines - adverse effects | Adult | Female | Aged | Myeloproliferative Disorders - complications | Patient Compliance | Platelet Aggregation Inhibitors - therapeutic use | Chronic Disease | Headache - chemically induced | Platelet Aggregation Inhibitors - adverse effects | Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap | Dose-Response Relationship; Drug | Klinisk medicin | MEDICINE | Hematologi | Thrombocytosis/drug therapy/etiology | Headache/chemically induced | Invärtesmedicin | Dermatologi och venerologi, klinisk genetik, invärtesmedicin | Diarrhea/chemically induced | Hematology | Internal medicine | Nausea/chemically induced | Myeloproliferative Disorders/complications | Dermatology and venerology,clinical genetics, internal medicine | Clinical Medicine | Haematology | MEDICIN | Heart Rate/drug effects | Quinazolines/adverse effects/therapeutic use | Platelet Aggregation Inhibitors/adverse effects/therapeutic use
Journal Article
Current Microbiology, ISSN 0343-8651, 09/2010, Volume 66, Issue 4, pp. 691 - 698
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | Index Medicus | Abridged Index Medicus | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | RECEPTOR GENE-MUTATIONS | MEDICINE, GENERAL & INTERNAL | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | NEVER-SMOKERS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article